title: BRAF inhibitors - do we need to worry about kidney injury?
authors.affiliation: a Nephrology Division , Hofstra Northwell School of Medicine, Northwell Health , Great Neck , NY , USA.
authors.forename: Rimda
authors.initials: R
authors.lastname: Wanchoo
authors.affiliation: b Division of Hematology/Oncology , Hofstra Northwell School of Medicine, Northwell Health, Northwell Cancer Institute , New Hyde Park , NY , USA.
authors.forename: Craig
authors.initials: C
authors.lastname: Devoe
authors.affiliation: a Nephrology Division , Hofstra Northwell School of Medicine, Northwell Health , Great Neck , NY , USA.
authors.forename: Kenar D
authors.initials: KD
authors.lastname: Jhaveri
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000453:epidemiology; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
keywords: BRAF inhibitors; acute renal failure; dabrafenib; melanoma; vemurafenib